Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes

OBJECTIVE: To examine the effect of combination therapy with canagliflozin plus liraglutide on HbA(1c), endogenous glucose production (EGP), and body weight versus each therapy alone. RESEARCH DESIGN AND METHODS: Forty-five patients with poorly controlled (HbA(1c) 7–11%) type 2 diabetes mellitus (T2...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Care
Hlavní autoři: Ali, Ali Muhammed, Martinez, Robert, Al-Jobori, Hussein, Adams, John, Triplitt, Curtis, DeFronzo, Ralph, Cersosimo, Eugenio, Abdul-Ghani, Muhammad
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2020
Témata:
Emerging Therapies: Drugs and Regimens
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7411279/
https://ncbi.nlm.nih.gov/pubmed/32220916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc18-2460
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky